1. Nebulisers comparison with inhaled tobramycin in young children with cystic fibrosis 
Aurélie Clavel, Audrey Boulaméry, Emmanuelle Bosdure, Caroline Luc, André Lanteaume, Guillaume Gorincour, Nathalie Stremler- Lebel, Jacques Sarles, Véronique Andrieu, Jean-Christophe Dubus 
Journal of Cystic Fibrosis 
Volume 6, Issue 2, Pages (April 2007)
DOI: /j.jcf
Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

2. Fig. 1
PariLC+ nebuliser (top: Pari GmbH, Munchen, Germany) and NL9M nebuliser (bottom: Diffusion Technique Française, Saint-Etienne, France) with their respective facemasks.
Journal of Cystic Fibrosis 2007 6, DOI: ( /j.jcf )
Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

3. Fig. 2
Individual ratio of tobramycin/creatinine obtained in 10 children with cystic fibrosis after inhaling 300 mg tobramycin with a PariLC+ and a NL9M nebuliser.
Journal of Cystic Fibrosis 2007 6, DOI: ( /j.jcf )
Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

4. Fig. 3
Median values of the ratio tobramycin/creatinine obtained in 10 children with cystic fibrosis after inhaling 300 mg tobramycin with a PariLC+ and a NL9M nebuliser.
Journal of Cystic Fibrosis 2007 6, DOI: ( /j.jcf )
Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions